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Thank you for taking the time to review our article.1 Your comments are valuable to us and will help us to revise our future related papers. 
Below are some points in response to the comments made 
by you.
The patient was admitted to our hospital during the 
peak stage of COVID-19 in our country. The decision for 
transferring the patient from ICU to the ward was made 
by our ICU managing team (including internal medicine 
specialists and anesthesiologists) because her respiratory 
situation was improved and she was extubated without any 
difficulties. Her O2 saturation was 92% with mask at the 
time we transferred her to the ward. Another reason for 
this decision was our limited ICU capacity, considering 
the fact that we had more critical ill patients waiting for a 
vacant bed in the ICU.
As we mentioned in the discussion part, critical illness 
neuropathy and myopathy usually occur in patients who 
stay in the ICU for a long time (at least ≥7 days). There 
are diagnostic criteria for critical illness neuropathy and 
myopathy. Having difficulties in weaning off of mechanical 
ventilation is one of the major diagnostic criteria for 
critical illness myopathy and neuropathy.2 Our patient was 
in the ICU for only 10 days and did not experience any 
respiratory deterioration during extubation and after that, 
during her stay in the ICU.
Moreover, patients with critical illness neuropathy and 
myopathy show signs and symptoms of muscle weakness 
and paresis while they are in the ICU. Our patient did not 
show any decreased muscle strength in her limbs during 
her stay in the ICU.
As we discussed in the article, the CSF protein levels are not 
elevated during the first week in Guillain- Barre syndrome. 
We obtained CSF and analyzed it for protein in the first 
week to exclude other differential diagnoses. We intended 
to repeat the CSF analysis when the disease progressed but 
unfortunately, it was not possible considering the patient’s 
situation. We faced several obstacles and limitations 
during the COVID-19 crisis. An intensive workup 
(including COVID-19 PCR on CSF samples) was not 
possible in many cases because of the increasing number 
of hospitalized patients with SARS-CoV-2 infection. 
Although COVID-19 PCR on CSF samples would be a 
very helpful tool to confirm the infection, it might not 
have a specific impact on our patient’s disease progression 
and outcome.
Again, thank you for your valuable comments.
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